These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7879246)

  • 1. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
    Carrieri G; Jordan ML; Shapiro R; Scantlebury VP; Vivas C; Kusne S; Magnone M; McCauley J; Starzl TE
    Transplant Proc; 1995 Feb; 27(1):961-3. PubMed ID: 7879246
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
    Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
    Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients.
    Nicol DL; MacDonald AS; Belitsky P; Lee S; Cohen AD; Bitter-Suermann H; Lowen J; Whalen A
    Transplantation; 1993 Apr; 55(4):841-6. PubMed ID: 8386404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
    Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
    Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.
    Basadonna G; Feria A; Perez R; Klein H; Sturges M; Colquhoun S
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):52-3. PubMed ID: 7940976
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis.
    Kizilisik TA; Preiksaitis JK; Kneteman NM
    Transplant Proc; 1993 Jun; 25(3):2282-3. PubMed ID: 8390739
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
    Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
    Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation.
    Solidoro P; Delsedime L; Costa C; Bergallo M; Libertucci D; Ruffini E; Rinaldi M; Baldi S
    New Microbiol; 2011 Jan; 34(1):33-6. PubMed ID: 21344144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of cytomegalovirus disease in renal allograft recipients.
    Balfour HH
    Scand J Infect Dis Suppl; 1991; 80():88-93. PubMed ID: 1725064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
    Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 14. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
    Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
    Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD
    Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
    Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
    Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.